Основная статистика
| LEI | 529900ESWZRHXOW27Z37 |
| CIK | 1384101 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Veracyte, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| August 6, 2025 |
Exhibit 99.1 Veracyte Announces Second Quarter 2025 Financial Results Grew total revenue to $130.2 million and testing revenue to $122.3 million, representing increases of 14% year-over-year Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., August 6, 2025 - Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the se |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| June 18, 2025 |
023 Equity Incentive Plan, as Amended EXHIBIT 10.1 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN, AS AMENDED (ADOPTED BY THE BOARD OF DIRECTORS ON APRIL 12, 2023, AS AMENDED JUNE 12, 2024 AND JUNE 17, 2025) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain, and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and A |
|
| June 17, 2025 |
Calculation of Filing Fee Tables S-8 VERACYTE, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.001 par value Other 2,500,000 $ 26.385 $ 65,962,500.00 0.0001531 $ 10,098.86 Total Offering Amounts: |
|
| June 17, 2025 |
As filed with the Securities and Exchange Commission on June 17, 2025 As filed with the Securities and Exchange Commission on June 17, 2025 Registration No. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| May 7, 2025 |
Exhibit 99.1 Veracyte Announces First Quarter 2025 Financial Results Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 7, 2025 - Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025 |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 28, 2025 |
Exhibit 19. VERACYTE, INC. Insider Trading Policy As Amended on February 12, 2025 1. Purpose. Both the Securities and Exchange Commission (the “SEC”) and the U.S. Congress are very concerned about maintaining the fairness and integrity of the U.S. capital markets. The securities laws are continually reviewed and amended to prevent people from taking advantage of “inside information” and to increas |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36156 VERACYTE, INC. |
|
| February 28, 2025 |
EXHIBIT 21.1 Veracyte, Inc. List of Subsidiaries Legal Entity Name Jurisdiction of Incorporation Veracyte International Corp. Delaware Veracyte Global, B.V. Netherlands Veracyte SD, Inc. Delaware Veracyte Labs SD Corporation Delaware Veracyte Diagnostics, LLC Delaware Veracyte SAS France Veracyte Labs VA Corporation Delaware C2i Genomics Ltd Israel |
|
| February 28, 2025 |
Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Veracyte, Inc. (the “Company,” “we,” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description summarizes certain terms of our capital stock and ce |
|
| February 24, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Nu |
|
| February 24, 2025 |
Exhibit 99.1 Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results Grew fourth quarter total revenue to $118.6 million, an increase of 21% Grew fourth quarter testing revenue to $112.2 million, an increase of 24% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., February 24, 2025 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the |
|
| November 12, 2024 |
VCYT / Veracyte, Inc. / Artisan Partners Limited Partnership - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. )* Veracyte Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP N |
|
| November 12, 2024 |
EX-99.1 2 d848164dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 11/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTI |
|
| November 8, 2024 |
VCYT / Veracyte, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Veracyte, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| November 8, 2024 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Veracyte, Inc. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Num |
|
| November 6, 2024 |
Exhibit 99.1 Veracyte Announces Third Quarter 2024 Financial Results Grew total revenue to $115.9 million, an increase of 29% Grew testing revenue to $109.5 million, an increase of 34% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., November 6, 2024 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024. “The |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Nu |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 6, 2024 |
Exhibit 99.1 Veracyte Announces Second Quarter 2024 Financial Results Grew total revenue to $114.4 million, an increase of 27% Grew testing revenue by 31% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., August 6, 2024 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2024. “Our exceptional second quarter results a |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| June 13, 2024 |
EXHIBIT 10.1 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN, AS AMENDED (AS AMENDED AND RESTATED JUNE 12, 2024) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain, and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering the |
|
| June 12, 2024 |
As filed with the Securities and Exchange Commission on June 12, 2024 As filed with the Securities and Exchange Commission on June 12, 2024 Registration No. |
|
| June 12, 2024 |
EXHIBIT 107.1 Calculation Of Filing Fee Tables Form S-8 (Form Type) Veracyte, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 |
|
| June 7, 2024 |
June 7, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| May 7, 2024 |
Exhibit 99.1 Veracyte Announces First Quarter 2024 Financial Results Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 7, 2024 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024. “We had a strong start to 2024, driven by robu |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 17, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File N |
|
| April 17, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF VERACYTE, INC. AND C2I GENOMICS INC. Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF VERACYTE, INC. AND C2I GENOMICS INC. On February 5, 2024, Veracyte, Inc. (“Veracyte” or the “Company”), a Delaware corporation, completed its acquisition of C2i Genomics, Inc. (“C2i”), a Delaware corporation, pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”), dated January 5, 2024, among t |
|
| April 17, 2024 |
C2I GENOMICS INC. CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 Exhibit 99.1 C2I GENOMICS INC. CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 INDEX Page Report of Independent Auditors 2-3 Consolidated Balance Sheet 4 Consolidated Statement of Operations 5 Consolidated Statement of Changes in Convertible Preferred Stocks and Stockholders' Equity (Deficiency) 6 Consolidated Statement of Cash Flows 7 Notes to Consolidated Financial Statements 8 – 28 - |
|
| March 22, 2024 |
1,016,965 Shares of Common Stock Veracyte, Inc. Table of Contents Filed pursuant to Rule 424(b)(7) Registration No. 333-277529 PROSPECTUS SUPPLEMENT (To Prospectus dated February 29, 2024) 1,016,965 Shares of Common Stock Veracyte, Inc. The selling stockholders of Veracyte, Inc. identified in this prospectus supplement (the “Selling Stockholders”) may offer and resell up to 1,016,965 shares of our common stock, par value $0.001 per share, under |
|
| March 22, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424B7 (Form Type) VERACYTE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Maximum Proposed Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Nu |
|
| February 29, 2024 |
2019 Stock Incentive Plan of C2i Genomics, Inc. Exhibit 10.27 C2I Genomics, Inc. 2019 Stock Incentive Plan Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of this 2019 Stock Incentive Plan (as amended, this “Plan”) is to afford an incentive to Service Providers of C2I Genomics, Inc., a corporation incorporated under the |
|
| February 29, 2024 |
Exhibit 4.1 VERACYTE, INC. TO [ ] as Trustee Indenture Dated as of , 20 Veracyte, Inc. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of , 20 Trust Indenture Act Section Indenture Sections § 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608 610 § 311(a) 613(a) (b) 613(b) (b)(2) 703(a)(2) 703(b) § 312(a) 701 702(a) (b) 702(b) |
|
| February 29, 2024 |
1,681,384 Shares of Common Stock Veracyte, Inc. Table of Contents Filed pursuant to Rule 424(b)(7) Registration No. 333-277529 PROSPECTUS SUPPLEMENT (To Prospectus dated February 29, 2024) 1,681,384 Shares of Common Stock Veracyte, Inc. The selling stockholders of Veracyte, Inc. identified in this prospectus supplement (the “Selling Stockholders”) may offer and resell up to 1,681,384 shares of our common stock, par value $0.001 per share, under |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36156 VERACYTE, INC. |
|
| February 29, 2024 |
Change of Control and Severance Agreement, effective Exhibit 10.26 VERACYTE, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between Phil Febbo(“Executive”) and Veracyte, Inc., a Delaware corporation (the “Company”), effective as of October 2, 2023 (the “Effective Date”). RECITALS 1. The Board of Directors of the Company (the “Board”) believes that it is |
|
| February 29, 2024 |
Form of Option Grant under the 2019 Stock Incentive Plan of C2i Genomics, Inc. Exhibit 10.28 NOTICE OF OPTION GRANT You have been granted the following options (the “Options”) to purchase shares of Common Stock par value US$0.001 each (the “Shares”) of C2I Genomics, Inc. (the “Company”), pursuant and subject to the terms and conditions of the Company’s ‘2019 Stock Incentive Plan’, a copy of which is attached hereto as Exhibit A (as may be amended from time to time, the “Plan |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 29, 2024 |
Exhibit 10.24 VERACYTE, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between John Leite (“Executive”) and Veracyte, Inc., a Delaware corporation (the “Company”), effective as of September 1, 2023 (the “Effective Date”). RECITALS 1. The Board of Directors of the Company (the “Board’’) believes that it |
|
| February 29, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424B7 (Form Type) VERACYTE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Maximum Proposed Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity |
|
| February 29, 2024 |
EXHIBIT 107.1 Calculation Of Filing Fee Tables Form S-8 (Form Type) Veracyte, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 per share |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 29, 2024 |
EXHIBIT 21.1 Veracyte, Inc. List of Subsidiaries Legal Entity Name Jurisdiction of Incorporation Veracyte International Corp. Delaware Veracyte Global, B.V. Netherlands Veracyte SD, Inc. Delaware Veracyte Labs SD Corporation Delaware Veracyte Diagnostics, LLC Delaware Veracyte SAS France Veracyte Labs VA Corporation Delaware C2i Genomics Ltd Israel |
|
| February 29, 2024 |
, between John Leite and the Registrant Exhibit 10.23 August 22, 2023 John Leite Dear John: Congratulations on your promotion! We are thrilled to support you in this next chapter of your career journey as Veracyte’s Chief Commercial Officer, CLIA! In line with your promotion, you will receive adjusted compensation to recognize your new position and responsibilities. The terms of the adjustments are as follows: 1. Effective September 1, |
|
| February 29, 2024 |
Form of Stock Option Assumption Notice by the Registrant to Option holders of C2i Genomics, Inc. Exhibit 10.29 VERACYTE, INC. STOCK OPTION ASSUMPTION NOTICE Dear [Full Name]: As you know, on [Date] (the “Closing Date”), Veracyte, Inc. (“Acquirer”) acquired C2i Genomics Inc. (the “Seller” and such transaction, the “Merger”) pursuant to the Agreement and Plan of Merger by and among Acquirer, Seller and certain parties named therein, dated January 5, 2024 (the “Merger Agreement”). Prior to the M |
|
| February 29, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE S-3ASR (Form Type) VERACYTE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Eq |
|
| February 29, 2024 |
Exhibit 97.1 Veracyte, Inc. Compensation Recovery Policy (Adopted April 28, 2023) The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives certain incentive-based compensation in the event of an accounting restatement resulting from material noncompliance w |
|
| February 29, 2024 |
Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2023, Veracyte, Inc. (the “Company,” “we,” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description summarizes the most importa |
|
| February 29, 2024 |
, between Phil Febbo and the Registrant Exhibit 10.25 September 11, 2023 Phil Febbo San Francisco, California Dear Phil, On behalf of Veracyte (Nasdaq: VCYT) (the “Company”), we are very pleased to offer you the position of Chief Medical Officer & Chief Scientific Officer pursuant to the terms of this letter (this “Offer Letter”). This position reports to Marc Stapley, Chief Executive Officer. This is a full-time exempt position. Your a |
|
| February 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Nu |
|
| February 22, 2024 |
Exhibit 99.1 Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results Grew Fourth Quarter Revenue to $98.2 million Increased 2023 Total Revenue 22% to $361.1 million Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., February 22, 2024 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2 |
|
| February 13, 2024 |
VCYT / Veracyte, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02198-veracyteinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Veracyte Inc Title of Class of Securities: Common Stock CUSIP Number: 92337F107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Num |
|
| February 12, 2024 |
EX-99.1 2 d755254dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 2/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTIS |
|
| February 12, 2024 |
VCYT / Veracyte, Inc. / Artisan Partners Limited Partnership - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Veracyte, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) 12/ |
|
| February 8, 2024 |
VCYT / Veracyte, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* VERACYTE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Num |
|
| January 29, 2024 |
VCYT / Veracyte, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm244117d27sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* Veracyte, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numb |
|
| January 8, 2024 |
Exhibit 99.1 For Immediate Release Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform Grew full-year revenue to between $358 million and $359 million, an increase of 21% Acquisition broadens Veracyte’s presence across the cancer care continuum SOUTH SAN FRANCISCO, Calif. — January 8, 2024 |
|
| November 8, 2023 |
Advisor Agreement, effective September 4, 2023, by and between Tina S. Nova and the Registrant Exhibit 10.1 August 7, 2023 Via Email Tina Nova, PhD Re: Advisory Services to Veracyte, Inc. Dear Tina: This letter agreement (this “Agreement”) is to confirm our understanding with respect to your service to Veracyte, Inc. (the “Company”) as an advisor of the Company. The Company looks forward to a continued mutually beneficial association with you on the following terms, which are hereby made ef |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Num |
|
| November 7, 2023 |
Exhibit 99.1 Veracyte Announces Third Quarter 2023 Financial Results Grew Total Revenue to $90.1 million, an Increase of 19% Grew Testing Revenue by 27% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., November 7, 2023 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2023. “I am pleased to share we delivered a |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| August 8, 2023 |
Exhibit 99.1 Veracyte Announces Second Quarter 2023 Financial Results Grew Total Revenue to $90.3 million, an Increase of 24% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., August 8, 2023 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2023. “We delivered outstanding second quarter results, with revenue and tes |
|
| June 9, 2023 |
VCYT / Veracyte Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* VERACYTE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) May 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| June 9, 2023 |
Amended and Restated Bylaws of the Registrant Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF VERACYTE, INC. (a Delaware corporation) As Amended and Restated on June 9, 2023 TABLE OF CONTENTS Page Article 1 Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article 2 Meeting of Stockholders 1 2.1 Place of Meeting 1 2.2 Annual Meeting 1 2.3 Special Meetings 5 2.4 Notice of Meetings 6 2.5 List of Stockholders 6 2.6 Organization and Conduct of Bus |
|
| June 9, 2023 |
Restated Certificate of Incorporation of the Registrant Exhibit 3.2 RESTATED CERTIFICATE OF INCORPORATION OF VERACYTE, INC. Veracyte, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: The name of the corporation is Veracyte, Inc. SECOND: The original Certificate of Incorporation of the corporation was filed with the Secretary of State of the State of Delaware on August 15, 2006 and t |
|
| June 9, 2023 |
Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF VERACYTE, INC. Veracyte, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: The name of the corporation is Veracyte, Inc. SECOND: The original Certificate of Incorporation of the corporation was filed with the Secretary of State of the State of Delaw |
|
| June 9, 2023 |
Form of agreements under the 2023 Equity Incentive Plan Exhibit 10.2 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN NOTICE OF GLOBAL STOCK OPTION GRANT Unless otherwise defined in this Notice of Global Stock Option Grant (this “Notice”), any capitalized terms used herein shall have the meaning ascribed to them in the Veracyte, Inc. (the “Company”) 2023 Equity Incentive Plan (the “Plan”). The individual named below (the “Participant”) has been granted an opt |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| June 8, 2023 |
Form of agreements under the 2023 Equity Incentive Plan Exhibit 99.6 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN NOTICE OF GLOBAL STOCK OPTION GRANT Unless otherwise defined in this Notice of Global Stock Option Grant (this “Notice”), any capitalized terms used herein shall have the meaning ascribed to them in the Veracyte, Inc. (the “Company”) 2023 Equity Incentive Plan (the “Plan”). The individual named below (the “Participant”) has been granted an opt |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 8, 2023 |
Form of agreements under the 2023 Equity Incentive Plan Exhibit 99.6 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN NOTICE OF GLOBAL STOCK OPTION GRANT Unless otherwise defined in this Notice of Global Stock Option Grant (this “Notice”), any capitalized terms used herein shall have the meaning ascribed to them in the Veracyte, Inc. (the “Company”) 2023 Equity Incentive Plan (the “Plan”). The individual named below (the “Participant”) has been granted an opt |
|
| June 8, 2023 |
Form of agreements under the 2023 Equity Incentive Plan Exhibit 99.6 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN NOTICE OF GLOBAL STOCK OPTION GRANT Unless otherwise defined in this Notice of Global Stock Option Grant (this “Notice”), any capitalized terms used herein shall have the meaning ascribed to them in the Veracyte, Inc. (the “Company”) 2023 Equity Incentive Plan (the “Plan”). The individual named below (the “Participant”) has been granted an opt |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 8, 2023 |
Form of agreements under the 2023 Equity Incentive Plan Exhibit 99.6 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN NOTICE OF GLOBAL STOCK OPTION GRANT Unless otherwise defined in this Notice of Global Stock Option Grant (this “Notice”), any capitalized terms used herein shall have the meaning ascribed to them in the Veracyte, Inc. (the “Company”) 2023 Equity Incentive Plan (the “Plan”). The individual named below (the “Participant”) has been granted an opt |
|
| June 8, 2023 |
Form of agreements under the 2023 Equity Incentive Plan Exhibit 99.6 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN NOTICE OF GLOBAL STOCK OPTION GRANT Unless otherwise defined in this Notice of Global Stock Option Grant (this “Notice”), any capitalized terms used herein shall have the meaning ascribed to them in the Veracyte, Inc. (the “Company”) 2023 Equity Incentive Plan (the “Plan”). The individual named below (the “Participant”) has been granted an opt |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 8, 2023 |
Form of agreements under the 2023 Equity Incentive Plan Exhibit 99.6 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN NOTICE OF GLOBAL STOCK OPTION GRANT Unless otherwise defined in this Notice of Global Stock Option Grant (this “Notice”), any capitalized terms used herein shall have the meaning ascribed to them in the Veracyte, Inc. (the “Company”) 2023 Equity Incentive Plan (the “Plan”). The individual named below (the “Participant”) has been granted an opt |
|
| June 8, 2023 |
Form of agreements under the 2023 Equity Incentive Plan Exhibit 99.6 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN NOTICE OF GLOBAL STOCK OPTION GRANT Unless otherwise defined in this Notice of Global Stock Option Grant (this “Notice”), any capitalized terms used herein shall have the meaning ascribed to them in the Veracyte, Inc. (the “Company”) 2023 Equity Incentive Plan (the “Plan”). The individual named below (the “Participant”) has been granted an opt |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 8, 2023 |
Form of agreements under the 2023 Equity Incentive Plan Exhibit 99.6 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN NOTICE OF GLOBAL STOCK OPTION GRANT Unless otherwise defined in this Notice of Global Stock Option Grant (this “Notice”), any capitalized terms used herein shall have the meaning ascribed to them in the Veracyte, Inc. (the “Company”) 2023 Equity Incentive Plan (the “Plan”). The individual named below (the “Participant”) has been granted an opt |
|
| June 8, 2023 |
Form of agreements under the 2023 Equity Incentive Plan Exhibit 99.6 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN NOTICE OF GLOBAL STOCK OPTION GRANT Unless otherwise defined in this Notice of Global Stock Option Grant (this “Notice”), any capitalized terms used herein shall have the meaning ascribed to them in the Veracyte, Inc. (the “Company”) 2023 Equity Incentive Plan (the “Plan”). The individual named below (the “Participant”) has been granted an opt |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 8, 2023 |
Form of agreements under the 2023 Equity Incentive Plan Exhibit 99.6 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN NOTICE OF GLOBAL STOCK OPTION GRANT Unless otherwise defined in this Notice of Global Stock Option Grant (this “Notice”), any capitalized terms used herein shall have the meaning ascribed to them in the Veracyte, Inc. (the “Company”) 2023 Equity Incentive Plan (the “Plan”). The individual named below (the “Participant”) has been granted an opt |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| May 4, 2023 |
Exhibit 99.1 Veracyte Announces First Quarter 2023 Financial Results Grew Total Revenue to $82.4 million, an Increase of 22% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 4, 2023 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2023. “We had an excellent first quarter, as many areas of our business greatly |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 1, 2023 |
Offer Letter, dated as of January 9, 2023, between Annie McGuire and the Registrant Exhibit 10.32 January 9, 2023 Ann McGuire Agoura, CA 91301 Dear Annie: We are excited to inform you that you will be promoted to Veracyte’s General Counsel and Chief People Officer. We believe this role will contribute to both your professional growth as well as Veracyte’s success. You will continue to report to Marc Stapley, CEO. Kindly note that the Company may modify job titles and reporting re |
|
| March 1, 2023 |
Separation Agreement dated December 13, 2022 between Giulia Kennedy and the Registrant EXHIBIT 10.28 VERACYTE, INC. December 13, 2022 Via Email Giulia Kennedy Re: Terms of Transition and Separation Dear Giulia: This letter confirms the agreement (“Agreement”) between you (“Executive” or “you”) and Veracyte, Inc. (the “Company”) concerning the terms of your transition and separation from employment and offers you certain benefits to which you would not otherwise be entitled, conditio |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36156 VERACYTE, INC. |
|
| March 1, 2023 |
Exhibit 10.33 VERACYTE, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between Ann McGuire (“Executive”) and Veracyte, Inc., a Delaware corporation (the “Company”), effective as of January 1, 2023 (the “Effective Date”). RECITALS 1. The Board of Directors of the Company (the “Board’’) believes that it |
|
| March 1, 2023 |
EXHIBIT 107.1 Calculation Of Filing Fee Tables Form S-8 (Form Type) Veracyte, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 per share |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| March 1, 2023 |
EXHIBIT 21.1 Veracyte, Inc. List of Subsidiaries Legal Entity Name Jurisdiction of Incorporation Veracyte International Corp. Delaware Veracyte Global, B.V. Netherlands Veracyte SD, Inc. Delaware Veracyte Labs SD Corporation Delaware Delight Merger Sub II, LLC Delaware Veracyte SAS France Veracyte Labs VA Corporation Delaware |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Nu |
|
| February 22, 2023 |
Exhibit 99.1 Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results Grew Fourth Quarter Revenue to $80.3 Million Grew 2022 Total Revenue to $296.5 Million Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., February 22, 2023 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2022. “We |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Num |
|
| February 10, 2023 |
Amended and Restated Bylaws of the Registrant Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF VERACYTE, INC. (a Delaware corporation) As Amended and Restated on February 9, 2023 TABLE OF CONTENTS Page Article 1 Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article 2 Meeting of Stockholders 1 2.1 Place of Meeting 1 2.2 Annual Meeting 1 2.3 Special Meetings 5 2.4 Notice of Meetings 6 2.5 List of Stockholders 6 2.6 Organization and Conduct of |
|
| February 10, 2023 |
VCYT / Veracyte Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Veracyte Inc (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 10, 2023 |
VCYT / Veracyte Inc / Artisan Partners Limited Partnership - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Veracyte, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) 12/ |
|
| February 10, 2023 |
VCYT / Veracyte Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 9, 2023 |
VCYT / Veracyte Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02170-veracyteinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Veracyte Inc. Title of Class of Securities: Common Stock CUSIP Number: 92337F107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule |
|
| February 9, 2023 |
VCYT / Veracyte Inc / WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm235848d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Veracyte, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number |
|
| February 6, 2023 |
VCYT / Veracyte Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* VERACYTE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Num |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Num |
|
| November 2, 2022 |
Exhibit 99.1 Veracyte Announces Third Quarter 2022 Financial Results Grew Total Revenue to $75.6 million, an Increase of 25% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., November 2, 2022 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2022. ?Our third quarter results were robust given test adoption growth |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| August 2, 2022 |
Exhibit 99.1 Veracyte Announces Second Quarter 2022 Financial Results Grew Total Revenue to $72.9 million, an Increase of 32% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., August 2, 2022 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2022. “Our second quarter results reflect our continued focus on execution, |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 4, 2022 |
Transition and Separation Agreement, effective February 21, 2022 EXHIBIT 10.5 February 21, 2022 Via Email Re: Terms of Transition and Separation Dear Jane: This letter confirms the agreement (?Agreement?) between you and Veracyte, Inc. (the ?Company?) concerning the terms of your transition and separation from employment and offers you certain benefits to which you would not otherwise be entitled, conditioned upon your provision of a general release of claims a |
|
| May 4, 2022 |
Change of Control and Severance Agreement, effective February 28, 2022 EXHIBIT 10.4 VERACYTE, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the ?Agreement?) is made and entered into by and between Ann (Annie) McGuire. (?Executive?) and Veracyte, Inc., a Delaware corporation (the ?Company?), effective as of February 28, 2022 (the ?Effective Date?). RECITALS 1. The Board of Directors of the Company (the ?Board?) believes |
|
| May 4, 2022 |
Change of Control and Severance Agreement, effective February 2, 2021 EXHIBIT 10.2 VERACYTE, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the ?Agreement?) is made and entered into by and between Tina S. Nova, PhD (?Executive?) and Veracyte, Inc., a Delaware corporation (the ?Company?), effective as of the closing (the ?Closing Date?) of the Company?s acquisition of Decipher Biosciences, Inc. (?Decipher?) pursuant to |
|
| May 4, 2022 |
EXHIBIT 10.6 April 20, 2022 Ms. Bonnie Anderson Delivered by hand or via email Dear Bonnie: Veracyte, Inc. (the ?Company?) is pleased to continue your employment as the Company?s Executive Chair (?Executive Chair?) on the terms set forth in this letter agreement (this ?Agreement?), effective April 20, 2022 (the ?Amendment Date?). This Agreement amends and restates in its entirety the letter agreem |
|
| May 4, 2022 |
Offer Letter, dated as of February 2, 2021, between Tina S. Nova and the Registrant EXHIBIT 10.1 February 2, 2021 Tina S. Nova, PhD Delivered by hand or via email Dear Tina: As you may know, Veracyte, Inc. (the ?Company? or ?Veracyte?)1 is entering into an agreement with Decipher Biosciences, Inc. (?Decipher?) , pursuant to which the Company will acquire Decipher (the ?Merger? and the closing thereof, the ?Closing Date?). This offer is contingent on the closing of the Merger, and |
|
| May 4, 2022 |
Offer Letter, dated as of February 7, 2022, between Annie McGuire and the Registrant EXHIBIT 10.3 02/07/2022 Annie McGuire Agoura Hills, CA Dear Annie: We?re delighted to confirm our offer of employment as Veracyte?s SVP, General Counsel. In this role, you will report to Marc Stapley, Chief Executive Officer. (You should note that the Company may modify job titles and reporting relationships from time to time as it deems necessary.) The terms of this offer are as follows: 1. You w |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| May 3, 2022 |
Exhibit 99.1 Veracyte Announces First Quarter 2022 Financial Results Grew Total Revenue to $67.8 million, an Increase of 85% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 3, 2022 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2022. "I am extremely pleased with our team?s strong results in the first quarte |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (a |
|
| March 1, 2022 |
EXHIBIT 107.1 Calculation Of Filing Fee Tables Form S-8 (Form Type) Veracyte, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 per share |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Nu |
|
| February 28, 2022 |
Exhibit 99.1 Veracyte Announces Fourth Quarter and Full-Year 2021 Financial Results Grew Fourth Quarter 2021 Revenue to $67.3 Million, an Increase of 95% Grew 2021 Revenue to $219.5 Million, an Increase of 87% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., February 28, 2022 - Veracyte, Inc., (Nasdaq: VCYT) today announced financial results for the fourth quarter and |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36156 VERACYTE, INC. |
|
| February 28, 2022 |
EXHIBIT 21.1 Veracyte, Inc. List of Subsidiaries Legal Entity Name Jurisdiction of Incorporation Veracyte International Corp. Delaware Veracyte Global, B.V. Netherlands Decipher Biosciences, Inc. Delaware Decipher Corp. Delaware Delight Merger Sub II, LLC Delaware Veracyte SAS France HalioDx Inc. Delaware |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2022 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Nu |
|
| February 14, 2022 |
VCYT / Veracyte Inc / Nikko Asset Management Americas, Inc. - SC13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Veracyte, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 92337F107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 10, 2022 |
VCYT / Veracyte Inc / WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Veracyte, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) December 31, 2021 (Date of Event Which |
|
| February 10, 2022 |
VCYT / Veracyte Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Veracyte Inc (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 10, 2022 |
VCYT / Veracyte Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Veracyte Inc. Title of Class of Securities: Common Stock CUSIP Number: 92337F107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 9, 2022 |
VCYT / Veracyte Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 4, 2022 |
VCYT / Veracyte Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VERACYTE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 4, 2022 |
VCYT / Veracyte Inc / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Veracyte, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 92337F107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| January 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numb |
|
| December 10, 2021 |
VCYT / Veracyte Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| November 9, 2021 |
Exhibit 99.1 Veracyte Announces Third Quarter 2021 Financial Results Total Revenue of $60.4 Million and Volume of 20,972 Tests Company Launches Percepta Nasal Swab and Decipher Bladder Genomic Tests; Completes Acquisition of HalioDx Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., November 9, 2021 ? Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for t |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Num |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 9, 2021 |
Exhibit 10.2 VERACYTE, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the ?Agreement?) is made and entered into by and between Rebecca Chambers (?Executive?) and Veracyte, Inc., a Delaware corporation (the ?Company?), effective as of July 19, 2021 (the ?Effective Date?). RECITALS 1. The Board of Directors of the Company (the ?Board??) believes that i |
|
| November 9, 2021 |
Exhibit 10.1 08/15/2021 Note: This Offer Letter amends and replaces the Offer Letter dated 6/24/21 Rebecca Chambers 4233 Ridgeway Drive San Diego, CA 92116 Dear Rebecca Chambers: We?re delighted to confirm our offer of employment as Veracyte?s Chief Financial Officer. In this role, you will report to Marc Stapley, Chief Executive Officer. (You should note that the Company may modify job titles and |
|
| September 9, 2021 |
Ran D. Ben-Tzur [email protected] | 650.335.7613 September 9, 2021 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Kevin Kuhar, Accounting Branch Chief Tara Harkins VIA EDGAR Re: Veracyte, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed February 22, 2021 Form 8-K filed March 15, 2021 File No. 001-36156 |
|
| August 10, 2021 |
VCYT / Veracyte Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| August 4, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| August 4, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(7) Registration No. 333-252681 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price Per Share (1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee (2) Common Stock, par value $0.001 per share 3,347,493 $39.30 $131,556,474.90 $14,353 (1) Estim |
|
| August 3, 2021 |
Unregistered Sales of Equity Securities, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| July 29, 2021 |
Employment Agreement, dated as of May 7, 2021, between Marc Stapley and the Registrant Exhibit 10.2 May 7, 2021 Mr. Marc Stapley Delivered by hand or via email Dear Marc: Veracyte, Inc.(the ?Company?) is pleased to offer you employment on the terms and conditions set forth in this letter agreement (this ?Agreement?). 1. Position. Effective as of June 1, 2021 (the ?Start Date?), you will be appointed as the Company?s Chief Executive Officer (?CEO?) reporting to the Company?s Board of |
|
| July 29, 2021 |
Exhibit 10.5 SECURITIES PURCHASE AND CONTRIBUTION AGREEMENT by and among VERACYTE, INC. and MI 3 SA SHAM Innovation Sant? BNP Paribas D?veloppement Sofipaca FPCI PSIM FIP Amundi France D?veloppement 2015 FIP Amundi France D?veloppement 4 Quest for Growth Philis Vincent Fert St?phane Debono Tabodar Corinne Danan Fabienne Hermitte Jerome Galon Employees Sellers Dated as of July 13, 2021 i |EU-DOCS\3 |
|
| July 29, 2021 |
Memorandum of Understanding between the Shareholders of HalioDx and the Registrant EXHIBIT 10.4 MEMORANDUM OF UNDERSTANDING by and among Veracyte, Inc. and MI 3 SA SHAM Innovation Sant? BNP Paribas D?veloppement Sofipaca FPCI PSIM FIP Amundi France D?veloppement 2015 FIP Amundi France D?veloppement 4 Quest for Growth Philis Vincent Fert St?phane Debono Tabodar Corinne Danan Fabienne Hermitte Jerome Galon June 1, 2021 -1- |EU-DOCS\32781015.1|| MEMORANDUM OF UNDERSTANDING dated Ju |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| July 29, 2021 |
Exhibit 99.1 Veracyte Announces Second Quarter 2021 Financial Results Total Revenue Increased 166% to $55.1 million; Genomic Volume Grew 215% to 20,856 Tests Company Advanced Clinical Evidence, Pipeline and Global Growth Strategy Raises 2021 Total Revenue Guidance Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July 29, 2021 ? Veracyte, Inc. (Nasdaq: VCYT) today anno |
|
| July 29, 2021 |
Employment Agreement, dated as of May 28, 2021, between Bonnie Anderson and the Registrant Exhibit 10.1 May 28, 2021 Ms. Bonnie Anderson Delivered by hand or via email Dear Bonnie: Veracyte, Inc. (the ?Company?) is pleased to offer you this letter agreement (this ?Agreement?) setting forth the terms and conditions of your transition to, and employment as, Executive Chairman of the Company. 1. Position. Effective as of June 1, 2021 (the ?Transition Date?) you will cease to be the Chief E |
|
| July 29, 2021 |
EXHIBIT 10.3 VERACYTE, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the ?Agreement?) is made and entered into by and between Marc Stapley (?Executive?) and Veracyte, Inc., a Delaware corporation (the ?Company?), effective as of June 1, 2021 (the ?Effective Date?). RECITALS 1. The Board of Directors of the Company (the ?Board?) believes that it is i |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| July 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| July 12, 2021 |
EXHIBIT 99.1 For Immediate Release Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth SOUTH SAN FRANCISCO, Calif., July 12, 2021 - Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Rebecca Chambers as executive vice president and chief financial officer. Ms. |
|
| June 8, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| June 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| June 8, 2021 |
Exhibit 99.1 For Immediate Release Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth Fueling growth by enabling IVD test development and manufacturing, deepening scientific capabilities and expanding cancer diagnostics scope to 8 of the 10 top cancers in the U.S. Investor conference call and webcast today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., June 1, 2021 ? Verac |
|
| June 1, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| June 1, 2021 |
Exhibit 99.1 For Immediate Release Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth Fueling growth by enabling IVD test development and manufacturing, deepening scientific capabilities and expanding cancer diagnostics scope to 8 of the 10 top cancers in the U.S. Investor conference call and webcast today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., June 1, 2021 ? Verac |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| May 19, 2021 |
EXHIBIT 99.1 Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection Company to hold webcast to discuss findings on Thursday, May 20, at 10:00 a.m. ET SOUTH SAN FRANCISCO, Calif., May 19, 2021 - Veracyte, Inc. (Nasdaq: VCYT) today announced pivotal clinical validation data showing that the company?s n |
|
| May 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| May 10, 2021 |
Exhibit 99.1 Veracyte Announces First Quarter 2021 Financial Results Total Revenue of $36.7 Million Increased 18%; Volume Grew 11% to 14,437 Tests Completed Acquisition of Decipher Biosciences, Expanding Reach Into 7 of the Top 10 Cancers in the United States Pivotal Validation Data for Percepta Nasal Swab Lung Cancer Test To Be Presented at ASCO Conference Call and Webcast Today at 4:30 p.m. ET S |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| May 10, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 10, 2021 |
EX-10.1 2 ex101deciphermergeragreeme.htm EX-10.1 DECIPHER MERGER AGREEMENT Exhibit 10.1 AGREEMENT AND PLAN OF MERGER by and among Veracyte, Inc., a Delaware corporation, Delight Merger Sub I, Inc., a Delaware corporation, Delight Merger Sub II, LLC a Delaware limited liability company, Decipher Biosciences, Inc., a Delaware corporation, and Fortis Advisors LLC, as the Stockholders’ Agent Dated as |
|
| April 23, 2021 |
Definitive Proxy Statement on Schedule 14A, filed on April 23, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| April 15, 2021 |
For Immediate Release Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results Keith Kennedy will retire following Q1 earnings release and 10-Q; Jane Alley appointed as acting CFO; Veracyte to conduct CFO search SOUTH SAN FRANCISCO, Calif. |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Number |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| March 15, 2021 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Numbe |
|
| March 3, 2021 |
2013 Stock Incentive Plan, as amended EXHIBIT 10.1 VERACYTE, INC. 2013 STOCK INCENTIVE PLAN (Adopted by the Board of Directors on October 2, 2013) (As amended by the Board of Directors on May 23, 2017, October 23, 2017 and February 26, 2021) 33857/00600/FW/11852899.4 Table of Contents Page Section 1. ESTABLISHMENT AND PURPOSE. 1 Section 2. DEFINITIONS. 1 Section 3. ADMINISTRATION. 5 Section 4. ELIGIBILITY. 7 Section 5. STOCK SUBJECT T |
|
| March 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Nu |
|
| February 22, 2021 |
As filed with the Securities and Exchange Commission on February 22, 2021 Registration No. |
|
| February 22, 2021 |
EX-21.1 5 vcyt-12312020xex211.htm EX-21.1 EXHIBIT 21.1 Veracyte, Inc. List of Subsidiaries Legal Entity Name Jurisdiction of Incorporation Veracyte International Corp. Delaware Veracyte Global, B.V. Netherlands |
|
| February 22, 2021 |
Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the EX-4.2 2 vcyt-12312020xex42.htm EX-4.2 Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2019, Veracyte, Inc. (the “Company,” “we,” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following |
|
| February 22, 2021 |
Exhibit 10.25 June 22,2020 James H. Erlinger III 6213 Carlyle Dr. Raleigh, NC 27614 Dear Jim: We?re delighted to confirm our offer of employment as Veracyte?s EVP, General Counsel. In this role, you will report to Bonnie Anderson, Chairman and Chief Executive Officer. (You should note that the Company may modify job titles and reporting relationships from time to time as it deems necessary.) The t |
|
| February 22, 2021 |
Amended and Restated Change in Control and Severance Agreement, effective Exhibit 10.24 VERACYTE, INC. CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control and Severance Agreement (the ?Agreement?) is made and entered into by and between James Erlinger III (?Executive?) and Veracyte, Inc., a Delaware corporation (the ?Company?), effective as of August 1, 2020 (the ?Effective Date?). RECITALS 1. The Board of Directors of the Company (the ?Board??) believes th |
|
| February 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36156 VERACYTE, INC. |
|
| February 17, 2021 |
Exhibit 99.1 Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results Fourth Quarter Revenue Increased 16% to $34.5 Million; Volume Grew 14% to 13,130 Tests Decipher Acquisition to Expand Global Leadership in Cancer Genomic Diagnostics While Accelerating Growth Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., February 17, 2021 - Veracyte, Inc., (Nasdaq: |
|
| February 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Nu |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 1)* Veracyte, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 92337F107 (CUSIP Number) December 31, 2020 (Date of Event whi |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Veracyte Inc (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Veracyte, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 92337F107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Veracyte, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 92337F107 (CUSIP Number) 12/31/2020 (Date of Event Which Require |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Veracyte Inc. Title of Class of Securities: Common Stock CUSIP Number: 92337F107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 5, 2021 |
Prospectus Filed Pursuant to Rule 424(b)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| February 5, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Num |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Veracyte, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 92337F107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 5, 2021 |
Underwriting Agreement dated February 4, 2021. Exhibit 1.1 VERACYTE, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT February 4, 2021 February 4, 2021 Goldman Sachs & Co. LLC SVB Leerink LLC As the Managers named in Schedule I hereto for the Underwriters named in Schedule II hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, New |
|
| February 5, 2021 |
Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock EX-99.1 Exhibit 99.1 Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–February 4, 2021–Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 7,432,433 shares of its common stock at a public offering price of $74.00 per share. The gross proceeds to the Compa |
|
| February 3, 2021 |
EX-99.1 Exhibit 99.1 For Immediate Release Veracyte To Acquire Decipher Biosciences Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics Expands TAM with presence in 7 of the 10 most common cancers Expected to accelerate revenue growth Tina Nova, Ph.D., Decipher Biosciences’ president and CEO, has left Veracyte’s board and will become Veracyte’s GM, urologic c |
|
| February 3, 2021 |
EX-4.1 Exhibit 4.1 VERACYTE, INC. TO [ ] Trustee Indenture Dated as of , 20 Veracyte, Inc. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of , 20 Trust Indenture Act Section Indenture Sections § 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608 610 § 311(a) 613(a) (b) 613(b) (b)(2) 703(a)(2) 703(b) § 312(a) 701 702(a) (b) 70 |
|
| February 3, 2021 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File |
|
| February 3, 2021 |
425 1 d93671d425.htm 425 Filed by Veracyte, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Companies: Veracyte, Inc. and Decipher Biosciences, Inc. This filing relates to a proposed business combination involving Veracyte, Inc. and Decipher Biosciences, Inc. (Subject Company Commission File No.: 001-36156) Decipher Biosciences Acquisition Further Solidifies Global L |
|
| February 3, 2021 |
425 Filed by Veracyte, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Companies: Veracyte, Inc. and Decipher Biosciences, Inc. This filing relates to a proposed business combination involving Veracyte, Inc. and Decipher Biosciences, Inc. (Subject Company Commission File No.: 001-36156) The following communications were made available by Veracyte on LinkedIn and Twit |
|
| February 3, 2021 |
425 Filed by Veracyte, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Companies: Veracyte, Inc. and Decipher Biosciences, Inc. This filing relates to a proposed business combination involving Veracyte, Inc. and Decipher Biosciences, Inc. (Subject Company Commission File No.: 001-36156) FEBRUARY 03, 2021 / 1:00PM GMT, Veracyte Inc To Acquire Decipher Biosciences Call |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Num |
|
| February 3, 2021 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 3, 2021 Registration No. |
|
| February 3, 2021 |
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results EX-99.2 3 d110946dex992.htm EX-99.2 Exhibit 99.2 For Immediate Release Veracyte Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results SOUTH SAN FRANCISCO, Calif., February 3, 2021— Veracyte, Inc. (Nasdaq: VCYT) today announced preliminary results for the fourth quarter and full year ended December 31, 2020. The company expects to report total revenue of between $34.0 million an |
|
| February 3, 2021 |
Filed by Veracyte, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Companies: Veracyte, Inc. and Decipher Biosciences, Inc. This filing relates to a proposed business combination involving Veracyte, Inc. and Decipher Biosciences, Inc. (Subject Company Commission File No.: 001-36156) Decipher Biosciences Acquisition Further Solidifies Global Leadership in Cancer Diagn |
|
| February 3, 2021 |
Subject to completion, dated February 3, 2021 Prospectus Filed Pursuant to Rule 424(b)(5) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2021 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Num |
|
| January 25, 2021 |
Restated Bylaws of the Registrant EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF VERACYTE, INC. (a Delaware corporation) Table of Contents Page Article 1 Offices.......................................................................... 1 1.1 Registered Office........................................................... 1 1.2 Other Offices................................................................. 1 Article 2 Meeting of Stockholder |
|
| December 16, 2020 |
EX-99.1 2 ex217949.htm EXHIBIT 99.1 VERACYTE PRESS RELEASE DATED DECEMBER 16, 2020 EXHIBIT 99.1 For Immediate Release Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests Data on Noninvasive Nasal Swab Test and Percepta Genomic Atlas Presented Today at Virtual Lung Cancer R&D Day SOUTH SAN FRANCISCO, Calif., December 16, 2020 - Veracyte, Inc. (Nasdaq: VCYT) an |
|
| December 16, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Nu |
|
| November 17, 2020 |
Exhibit 99.1 For Immediate Release Veracyte Announces New General Manager Structure to Advance Global Expansion John Hanna appointed GM, endocrinology, breast cancer and lymphoma; Morten Frost to join company as GM, pulmonology SOUTH SAN FRANCISCO, Calif., November 17, 2020 - Veracyte (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company?s growing roster of ge |
|
| November 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2020 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36156 20-5455398 (State or other jurisdiction of incorporation) Commission File Nu |
|
| November 2, 2020 |
Exhibit 99.1 For Immediate Release Veracyte Announces Third Quarter 2020 Financial Results Revenue of $31.1 Million; Product and Testing Revenue Increased 79% Over Second Quarter of 2020 Achieved Key Reimbursement Milestones Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., November 2, 2020- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third |
|
| November 2, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 2, 2020 |
Form of stock option award agreement under 2013 Stock Incentive Plan Exhibit 10.1 Veracyte, Inc. 2013 Stock Incentive Plan Notice of Stock Option Grant Optionee Name and Address: [-] Option Number: [-] Doc Reference: [-] EEO-ID: [-] You have been granted the following Option to purchase shares of Common Stock of Veracyte, Inc. (the “Company”) under the Company’s 2013 Stock Incentive Plan (the “Plan”). The Option is subject to the terms and conditions set forth in t |
